0001356576-19-000049.txt : 20191212 0001356576-19-000049.hdr.sgml : 20191212 20191212161222 ACCESSION NUMBER: 0001356576-19-000049 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20191209 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191212 DATE AS OF CHANGE: 20191212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 191281985 BUSINESS ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 1550 E GUDE DR CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 8-K 1 a8-k12x9x19spn810301re.htm 8-K Document
false0001356576 0001356576 2019-12-09 2019-12-09


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): December 9, 2019
 
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-35518
20-2590184
 
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
 
 
 
1550 East Gude Drive
Rockville
MD
20850
 
(Address of Principal Executive Offices)
 
(Zip Code)
 

 
Registrant’s telephone number, including area code: (301) 838-2500
 
Not Applicable
(Former name or former address, if changed since last report.)

  Securities registered pursuant to Section 12(b) of the Exchange Act
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.001 par value per share
SUPN
The Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 



1


Item 8.01                                           Other Events.
 
On December 9, 2019, Supernus Pharmaceuticals, Inc. (the “Company”) issued a press release announcing an update on the results from the first Phase III study (P301) of SPN-810, a novel treatment of Impulsive Aggression in patients with attention deficit hyperactivity disorder. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.


 
Item 9.01                                           Financial Statements and Exhibits.
 
(d)                                 Exhibit
 
The following document is furnished as an Exhibit pursuant to Item 8.01 hereof:
 
Exhibit 99.1 — Press Release Dated December 9, 2019.

Exhibit 104 — The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.



2


EXHIBIT INDEX
 
Number
 
Description
 
 
 
 
 
 
 
99.1
 
 
Attached

3


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
 
SUPERNUS PHARMACEUTICALS, INC.
 
 
DATED: December 12, 2019
By:
/s/ Gregory S. Patrick
 
 
Gregory S. Patrick
 
 
Senior Vice-President and Chief Financial Officer


4
 EX-99.1 2 ex99112-9x19.htm EXHIBIT 99.1 Exhibit


Exhibit 99.1
 logoa06.jpg
 

Supernus Provides Update on Results from
Phase III Study (P301) of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients

ROCKVILLE, Md., December 9, 2019 - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, is providing an update on the results from the first Phase III study (P301) of SPN-810, a novel treatment of Impulsive Aggression (IA) in patients with ADHD.

In early November 2019, the Company reported topline results from the Phase III P301 trial in patients 6 to 11 years. The study was a randomized, double-blind, placebo controlled, multicenter, parallel group clinical trial in patients diagnosed with ADHD. Patients receiving SPN-810 36mg showed a median percent reduction of 58.6% in the average weekly frequency of impulsive aggression episodes from baseline that was not statistically significant (p=0.092) compared to placebo. These results are based on the combined analysis of data from stages 1 and 2 in the study. In stage 1 (interim analysis stage), the median percent reduction was 60.0%, which was statistically significant (p=0.029) compared to placebo. However, in stage 2 of the P301 study, post the interim analysis, the increase in variability in the 36mg treatment arm seems to have adversely impacted the results in the combined analysis.

After conducting further analysis on the P301 data, the Company believes that the high variability in the 36mg treatment arm was primarily due to 6 patients out of 135 that had a mild IA condition with a baseline score of 6 episodes or less per week. In the placebo arm, there were 7 patients with the same mild IA condition. By excluding these subjects from the placebo and the 36mg treatment arm, the primary analysis (combined stage 1 and 2 data) of the P301 data on the primary endpoint results in a p value of 0.017 for the treatment arm compared to placebo. This positive result is also confirmed by the sensitivity analysis on the primary endpoint with a p value of 0.044.

Percent Change from Baseline (CFB) in the Frequency of IA Behaviors
Treatment Period - Primary Analysis (ITT Population)

 
Original Analysis
Analysis Excluding Patients with Baseline Score of 6 or less Episodes per Week
Stage 1 - % CFB
Placebo
SPN-810
36mg
Placebo
SPN-810
36mg
   N
52
45
50
44
   Mean (SD)
-42.9 (35.9)
-56.6 (34.1)
-44.8 (29.9)
-55.6 (33.8)
   Median
-48.6
-60.0
-48.6
-57.8
   P-value
 
0.029
 
0.039
Stage 2 - % CFB
 
 
 
 
   N
73
90
68
85
   Mean (SD)
-43.8 (36.3)
-44.0 (43.5)
-42.0 (35.3)
-49.1 (36.6)
   Median
-47.2
-58.5
-46.2
-59.2
   P-value
 
0.5370
 
0.119
Stages 1 & 2 Combined - % CFB
 
 
 
 
   N
125
135
118
129
   Mean (SD)
-43.4 (36.0)
-48.2 (40.9)
-43.2 (33.0)
-51.3 (35.7)
   Median
-48.2
-58.6
-47.2
-59.2
   P-value
 
0.092
 
0.017





The Company plans on finalizing the statistical plan (SAP) for the second Phase III P302 study in patients 6 to 11 years old taking into consideration the exclusion of patients with 6 or less episodes of IA per week. The Company will be submitting the SAP to the Food and Drug Administration (FDA) and expects data from the P302 study in the first quarter of 2020.

The P503 adolescent Phase III study in patients 12 to 17 years old had been designed from the outset with an exclusion criterion that excludes patients with a baseline score of 6 or less episodes per week.

“Based on this new analysis, we are hopeful that the second Phase III study will be positive, and if so, that future discussions with the FDA will be productive in progressing this potential novel treatment,” said Jack Khattar, President and CEO of Supernus. “While there are no assurances that SPN-810 will eventually progress forward and obtain FDA approval, we continue to believe that with a clinically meaningful reduction of approximately 60% in IA episodes, it can be a real treatment option for patients who currently have no proven products to help them manage their condition," added Mr. Khattar.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD and SPN-604 for the treatment of bipolar disorder.
Forward-Looking Statements:
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products; the Company’s ability to increase its net revenue; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates including SPN-810; the Company’s ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.









CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591

or

INVESTOR CONTACT:
Peter Vozzo
Westwicke, an ICR Company
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com

 





 EX-101.SCH 3 supn-20191209.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 supn-20191209_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 supn-20191209_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 supn-20191209_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Filer Name Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key EX-101.PRE 7 supn-20191209_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 logoa06.jpg begin 644 logoa06.jpg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�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end JSON 9 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8-k12x9x19spn810301re.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "supn-20191209_cal.xml" ] }, "definitionLink": { "local": [ "supn-20191209_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a8-k12x9x19spn810301re.htm" ] }, "labelLink": { "local": [ "supn-20191209_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "supn-20191209_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "supn-20191209.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "supn", "nsuri": "http://www.supernus.com/20191209", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-k12x9x19spn810301re.htm", "contextRef": "D2019Q4Q4201912-9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.supernus.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-k12x9x19spn810301re.htm", "contextRef": "D2019Q4Q4201912-9", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity Filer Name" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.supernus.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 10 a8-k12x9x19spn810301re_htm.xml IDEA: XBRL DOCUMENT 0001356576 2019-12-09 2019-12-09 false 0001356576 8-K 2019-12-09 Supernus Pharmaceuticals, Inc. DE 001-35518 20-2590184 1550 East Gude Drive Rockville MD 20850 301 838-2500 Common Stock, $0.001 par value per share SUPN NASDAQ false false false false false ZIP 11 0001356576-19-000049-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001356576-19-000049-xbrl.zip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end XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 97 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.supernus.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports a8-k12x9x19spn810301re.htm ex99112-9x19.htm supn-20191209.xsd supn-20191209_cal.xml supn-20191209_def.xml supn-20191209_lab.xml supn-20191209_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
Dec. 09, 2019
Cover page.  
Document Type 8-K
Document Period End Date Dec. 09, 2019
Entity Registrant Name Supernus Pharmaceuticals, Inc.
Entity Incorporation, State or Country Code DE
Entity Filer Name 001-35518
Entity Tax Identification Number 20-2590184
Entity Address, Address Line One 1550 East Gude Drive
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 838-2500
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol SUPN
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001356576
EXCEL 17 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end